Multi-chain chimeric polypeptides for immune cell stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, aging-related diseases, and infectious diseases often lack effective methods to stimulate immune cells, enhance their proliferation, or differentiate them into memory-like cells, which are crucial for sustained immune responses.
Innovation Solution
The development of multi-chain chimeric polypeptides that include target-binding domains, a soluble tissue factor domain, and affinity domains, which associate through specific binding interactions, are designed to stimulate, proliferate, and differentiate immune cells, thereby enhancing immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cancer, aging-related diseases, and infectious diseases, then existing therapeutic approaches are maintained, but effective stimulation of immune cells, enhancement of proliferation, and differentiation into memory-like cells is insufficient
Solution Approach 1:
The patent combines multiple functional domains into a single chimeric polypeptide molecule: a TGF-β binding domain (for target recognition), a tissue factor domain (for immune cell stimulation), and an IL-15 domain (for proliferation and differentiation signals). This merging of previously separate therapeutic functions into one integrated molecule enables simultaneous immune cell stimulation, proliferation enhancement, and memory cell differentiation, directly resolving the contradiction between reliability and adaptability.
Solution Approach 2:
The chimeric polypeptide is designed with multi-functionality to address multiple immune therapeutic needs simultaneously. The TGF-β binding domain provides target specificity, the tissue factor domain enables immune cell activation, and the IL-15 domain promotes proliferation and memory cell formation. This universal design allows a single agent to perform multiple functions that were previously requiring separate treatments, enhancing both reliability and adaptability of immune cell stimulation.
2Reliability
If multi-chain chimeric polypeptides with multiple functional domains are developed, then immune cell stimulation, proliferation, and differentiation are enhanced, but molecular complexity increases
Solution Approach 1:
The chimeric polypeptide is segmented into distinct functional domains that can be independently designed and optimized: the TGF-β binding domain segment handles target recognition, the tissue factor segment provides immune activation, and the IL-15 segment drives proliferation. This segmentation allows each domain to be carefully engineered for its specific function while maintaining overall molecular organization, managing complexity through structured modularity.
Solution Approach 2:
The invention creates a composite protein structure by fusing different functional domains from various sources into a single chimeric molecule. The tissue factor domain and IL-15 domain are combined with the TGF-β binding domain to create a composite polypeptide that integrates multiple biological activities. This composite approach enables complex immune modulation functions while maintaining a unified molecular structure that can be produced and administered as a single therapeutic agent.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These multi-chain chimeric polypeptides effectively stimulate immune cell activity, increase their proliferation, and induce differentiation into memory-like cells, potentially leading to improved treatments for cancer, aging-related diseases, and infectious diseases.
Implementation Method 1
Binding of the serine protease FVIIa to tissue factor promotes rapid cleavage of FX to FXa and FIX to FIXa. The proteolytic activity of the resulting FXa and an active membrane surface then inefficiently converts a small amount of prothrombin to thrombin.
Implementation Method 2
Tissue factor (TF), a 263 amino acid integral membrane glycoprotein with a molecular weight of ∼46 kDa and the trigger protein of the extrinsic blood coagulation pathway, is the primary initiator of coagulation in vivo.
Implementation Method 3
Following cellular damage, activation, or increased levels of cytosolic Ca2+, this bilayer asymmetry is lost, resulting in increased PS exposure on the outer leaflet, which increases the specific activity of cell-surface tissue factor-FVIIa complexes.
Data Source
AI summary
Provided herein are multi-chain chimeric polypeptides and uses thereof for treating cancer, aging related diseases or conditions, and/or an infectious disease. Further provided, are methods for stimulating an immune cell, inducing or increasing proliferation of an immune cell, and/or inducing differentitation of an immune cell into a memory-like immune cell by contacting the immune cell with the multi-chain chimeric polypeptides disclosed herein.